MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study

with No hi ha comentaris
  • Janjigian, Y. Y., Van Cutsem, E., Muro, K., Wainberg, Z. A., Al-Batran, S. E., Hyung, W. J., . . . Tabernero, J. (2021). MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study. Journal of Clinical Oncology, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4151 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *